Three Largest U.S. Generic Firms See Diversification As Best Path Through Reverse Patent Cliff

Expanded technological capabilities, narrowed focus on alternative dosage forms and harder-to-replicate products, and growing international reach are among the strategies being employed by Teva, Mylan and Watson in the face of 2013’s anticipated reverse patent cliff.